PharmaResearch Partners with VIVACY for Expanded European Reach

Expanding Reach with New Global Partnerships

PharmaResearch has taken a significant step in strengthening its distribution capabilities across the European market. By forming a strategic partnership with VIVACY, a renowned medical aesthetics corporation, they aim to enhance the availability of their innovative medical device brand, Rejuran, throughout Europe.

Strategic Collaboration with VIVACY

VIVACY, based in France, boasts a strong market presence and expertise in aesthetic medicine, making this collaboration highly beneficial. This partnership will leverage both companies’ strengths—PharmaResearch's advanced regenerative medicine solutions and VIVACY's comprehensive distribution network that spans several key markets across Europe.

VIVACY's Market Strength

Headquartered in France, VIVACY is prominent in the realm of medical aesthetics, offering superior quality products. Their vast network ensures efficient reaching of various European markets, establishing a solid foundation for the launch of Rejuran. This collaboration not only seeks to elevate Rejuran's visibility but also aims to enhance consumer access to cutting-edge regenerative treatments.

Details of the Agreement

This strategic distribution agreement is valued at approximately EUR 54.5 million over the next five years and encompasses a reach into 22 European countries, covering critical markets. This includes countries like the United Kingdom, Germany, France, Italy, and Spain—each known for their evolving and expansive cosmetic sectors.

Future Distribution Plans

PharmaResearch plans to initiate product distribution within critical European markets soon. They aim for a gradual rollout strategy that will expand their footprint in adjacent markets, providing consumers with timely access to their innovative solutions.

Company Perspectives

Jihoon Sohn, CEO of PharmaResearch, expressed confidence in the partnership's potential, noting that Rejuran is currently the only Polynucleotide-based medical device approved under the EU Medical Device Regulation (MDR). This distinction provides an excellent opportunity to fortify Rejuran's position in the global market.

Enhancing Global Visibility

In his statement, Sohn emphasized their commitment to elevating Rejuran's global presence as a premier skin booster in the international medical aesthetics arena. This partnership represents a major advancement towards achieving that goal.

Commitment to Quality and Innovation

The partnership was also praised by Bertrand, the CEO of VIVACY, who recognized the quality and efficacy of Rejuran's premium brand positioning. He highlighted the vital blend of VIVACY's scientific reputation with PharmaResearch's innovative technology as a key factor for success in entering the European market.

About PharmaResearch

PharmaResearch is recognized as a pioneering biopharmaceutical firm committed to enhancing the quality of life through innovative regenerative medicine. Their extensive portfolio includes pharmaceuticals, medical devices, cosmetics, and supplements. The company focuses on leveraging their unique core ingredients, protected by a collection of patents, to deliver effective health solutions.

Conclusion

This strategic partnership not only broadens PharmaResearch’s reach in Europe but also signifies a crucial development in the medical aesthetics industry, setting the stage for innovative treatment options like Rejuran to become more accessible across the continent.

Frequently Asked Questions

What is the focus of PharmaResearch?

PharmaResearch is dedicated to advancing regenerative medicine to improve the quality of life through innovative treatments and products.

What product is being distributed in Europe?

The product being distributed is Rejuran, a Polynucleotide-based medical device aimed at enhancing skin aesthetics.

How large is the distribution partnership?

The partnership with VIVACY covers an agreement valued at approximately EUR 54.5 million over five years, reaching 22 countries.

What distinguishes Rejuran in the market?

Rejuran is the only Polynucleotide-based medical device approved under the EU Medical Device Regulation, marking its uniqueness in the market.

When is PharmaResearch planning to launch in Europe?

PharmaResearch intends to start distribution in key European countries soon, with phased rollouts planned for broader market access.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.